Valproate and the symptomatic treatment of schizophrenia spectrum patients

Pharmacopsychiatry

Volumn 33, Issue 5, 2000, Pages 182-188

  Winterer, G ^a,b   Hermann, W M ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMIC ACID; RNA; SEROTONIN; SODIUM CHANNEL; VALPROIC ACID;

AGGRESSION; ARTICLE; CELL MEMBRANE FLUIDITY; DRUG EFFECT; GABAERGIC SYSTEM; GENE EXPRESSION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESTLESSNESS; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; TEMPORAL LOBE;

CLINICAL TRIALS; GABA AGENTS; HUMANS; SCHIZOPHRENIA; VALPROIC ACID;

EID: 0033798197     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-12981     Document Type: Article

References (114)

1. Schizophrenia, sensory gating, and nicotinic receptors
2. Electrophysiologic analysis of the actions of valproate on pyramidal neurons in the rat hippocampal slice
3. Suicide in affective and shcizoaffective disorders
4. Le valpromide (Depamide) dans le traitement d'etats psychotiques aigus
5. Brain SPECT findings and aggressiveness
6. Positive and negative symptoms: Assessment and validity
7. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH- SY5Y cells
8. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy
9. Evidence for altered trisynaptic circuitry in schizophrenic hippocampus
10. Regionally specific neuronal pathology in untreated patients With schizophrenia: A proton magnetic resonance spectroscopic imaging study
11. The effect of sodium valproate on extracellular GABA and other aminoacids in the rat ventral hippocampus: An in vivo microdialysis study
12. Effect of valproate on the metabolism of the central nervous system
13. The course and outcome of cycloid psychosis
14. Effects of valproic acid in cultured mammalian neurons
15. Causes of death in DSM-III schizophrenics and other psychotics (atypical group): A comparison with the general population
16. Psychiatric phenomenon in Alzheimer's disease. IV: Disorders of behaviour
17. Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: A possible intermediate neurobiological phenotype
18. Augmentation of resperidone with valproic acid
19. Utilization of valproate: Extent of inpatient use in the New York State Office of Mental Health
20. Neurological substrates of aggressive behavior
21. Cycloid psychosis: An investigation of the diagnostic concept
22. Valproic acid - A reappraisal of its pharmacological properties and clinical efficacy in epilepsy
23. Carbamazepine increases extracellular serotonin concentration: Lack of antagonism by terodotoxin or zero Ca2+
24. Carbamazepine-induced release of serotonin from rat hippocampus in vitro
25. Aggression and defense under cerebral ratio control
26. Naturalistic experience with the use of divalproex sodium on an in-patient unit for adolescence psychiatric patients
27. A practical guide to the management and prevention of migraine
28. The antibipolar drug valporate mimics lithium in stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain cortex slices but not accumulation of inositol monophosphates and biphosphates
29. Divalproex treatment of disrupture adolescents: A report of 10 cases
30. Combined treatment of schizophrenic psychoses with haloperidol and valproate
31. The Use of Sodium valproate, carabamazepine, and oxcarbazepine in patients with affective disorders
32. Potential impact of valproic acid therapy on clozapine disposition
33. The effect of sodium valproate on tardive dyskinesia - Revisited
34. Les troubles du comportement chez les epileptiques psychomoteurs
35. Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices
36. Effects of Dl-n-proylacetate, and anticonvulsive compound, on GABA metabolism
37. A review of anticonvulsants in treating agitated demented elderly patients
38. Divalproex: A possible treatment alternative for demented, elderly aggressive patients
39. Valproic acid treatment of agitation in dementia
40. Epileptic anamnesis
41. Intravenous valproate for rapid stabilization of agitationin neuropsychiatric disorders
42. Pharmacological, developmental, and physiological regulation of synaptic membrane phospholipids
43. Neuroanatomical and neurochemical pathology in schizophrenia
44. Initiation and adaptation: A paradigm for understanding psychotropic drug action
45. Effect of sodium valproate in three patients with organic brain syndrome
46. Long-term administration of valproic acid in the treatment of affective symptoms in mental retardation
47. Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics
48. The neurobiology of impulse aggression
49. Divalproex sodium for impulse aggressive behavior in patients with personality disorder
50. Valproate and carbamazepine in the treatment of panic and post-traumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes
51. New developments in the pharmacologic treatment of schizoaffective disorder
52. Valproic acid use in psychiatry issues in treating women of reproductive age
53. Magnetic resonance spectroscopy in schizophrenia and psychotic disorders
54. Effects of valporic acid on behavior and plasma amino acid concentration in chronic schizophrenic patients
55. Successful treatment of episodic dyscontrol with carbamazepine
56. The secondary schizophrenias
57. Drug treatment of mania: A critical review
58. Effect of sodium valproate on tardive dyskinesia
59. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia
60. Effect of inhibitors of GABA aminotransferase on the metabolism of gGABA in brain tissue and synaptosomal fractions
61. In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats
62. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain
63. Valproic acid effects on serum concentration of clozapine and norclozapine
64. Valproate in the treatment of behavioral agitation in elderly patients with dementia
65. Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions
66. Clinically significant interactions of psychotropic agents with antipsychotic drugs
67. Sodium valproate: Its use in primary psychiatric disorders
68. Valproate in primary psychiatric disorders: Literature review and clinical experience in a private psychiatric hospital
69. Valproate in psychiatric disorders: Literature review and clinical guidelines
70. Treatment of the neuroleptic-nonreponsive schizophrenic patient
71. Treatment of resistant schizophrenia with valporate and neuroleptic drugs
72. Glutamate receptor dysfunction and schizophrenia
73. GABAergic drugs and socio-sexual behavior
74. Failure of the antiepileptic drug valproic acid to modify synaptic and non-synaptic responses of CA1 hippocampal pyramidal cells maintained 'in vitro'
75. Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine
76. Valproate enhances inhibitory postsynaptic potentials in hippocampal neurons in vitro
77. Effect of valproate on cognitive functioning
78. Developmental changes in synaptic membrane order: A comparison of regions in the rat brain
79. Valproate and neuroleptic medication
80. Valproate in anxiety and withdrawal syndromes
81. Amygdalohippocamectomy for pathological aggression
82. Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA
83. Antiepileptic drug actions
84. 3-Alkyl-4-aminobutyric acids; the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase
85. An open trial of valproate in borderline personality disorder
86. Schizophrenia and the risk of violence
87. Schizoaffective disorder
88. The relationship between plasma concentration of valproic acid and its anti-convulsant and behavioral effects in rat
89. Lipid structural order parameter (reciprocal of fluidity) in biomembranes derived from steady-state fluorescence polarization measurements
90. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase
91. Brain glucose metabolism in violent psychiatric patients: A preliminary study
92. Effects of short-term prenatal alcohol exposure on neuronal membrane order in rats
93. Prenatal phenytoin exposure decreases neuronal membrane order in rat offspring hippocampus
94. Fetal anticonvulsant syndrome in rats: Dose- and period-response relationships of prenatal diphenylhydantoin, trimehadione, and phenobarbital exposure on the structural and functional development of the offspring
95. Fetal anticonvulsant syndrome in rats: Effects on postnatal behavior and brain amino acid content
96. Behavioral teratogenicity of valproic acid: Selective effects on behavior after prenatal exposure to rats
97. Prenatal valproic acid exposure decreases neuronal membrane order in rat offspring hippocampus and cortex
98. Effects of valproate on amino acid and monoamine concentrations in triatum of audiogenic seizure-prone Balb/c mice
99. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78
100. Implications of normal brain development for the pathogenesis of schizophrenia
101. Cell Biology of the hippocampal formation in schizophrenia
102. Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain
103. Divalproex sodium as a treatment for borderline personality disorder
104. Schizophrenia: Reduced Signal-to-Noise Ratio and Impaired Phase-Locking during Information Processing
105. An association between reduced interhemispheric EEG coherence in the temporal lobe and genetic risk for schizophrenia
106. Rational polypharmacy in schizophrenia
107. Electroencephalography, computed tomography and violence ratings of male patients in a maximum security mental hospital
108. Effectiveness of valproic acid on destructive and aggressive behaviors in patients with acquired brain injury
109. Pharmacologic traetment of aggression
110. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro